Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (22433)	6/17/1998 10:46:00 PM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

Bob, >Well, which is it, clarification or deficiencies? I wonder. But I have a hard time reconciling deficiencies in the drug itself with the advisory panel vote. If it is the application per se that needs to be cleaned up a bit, then this is all trivial. It seems to me that the advisory panel was clear on the clinical benefit and the safety issues. Does anyone know if this is unusual for a fast-track application? It seems pretty obvious that the FDA did this on the last day just to stop the clock and gain some breathing room. Thanks, Torben P.S. Yes, I did get back. I barely made it out of Norway before the ATC strike. I had to take a 4am flight in order to avoid a strike that started at 8am!